Lyra Therapeutics Inc (NASDAQ:LYRA) shares, rose in value on Wednesday, April 16, with the stock price down by -0.22% to the previous day’s close as strong demand from buyers drove the stock to $0.09.
Actively observing the price movement in the last trading, the stock closed the session at $0.09, falling within a range of $0.0834 and $0.0945. The value of beta (5-year monthly) was 0.043. Referring to stock’s 52-week performance, its high was $5.77, and the low was $0.08. On the whole, LYRA has fluctuated by -42.36% over the past month.
With the market capitalization of Lyra Therapeutics Inc currently standing at about $6.06 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-12.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 160k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LYRA’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of LYRA currently trading nearly -25.94% and -44.03% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 30.43, while the 7-day volatility ratio is showing 22.05% which for the 30-day chart, stands at 15.38%. Furthermore, Lyra Therapeutics Inc (LYRA)’s beta value is 0.13, and its average true range (ATR) is 0.02.
A comparison of Lyra Therapeutics Inc (LYRA) with its peers suggests the former has fared considerably weaker in the market. LYRA showed an intraday change of -0.22% in last session, and over the past year, it shrunk by -98.25%%.
Data on historical trading for Lyra Therapeutics Inc (NASDAQ:LYRA) indicates that the trading volumes over the past 10 days have averaged 2.19 and over the past 3 months, they’ve averaged 1.11 million. According to company’s latest data on outstanding shares, there are 65.52 million shares outstanding.
Nearly 16.73% of Lyra Therapeutics Inc’s shares belong to company insiders and institutional investors own 37.92% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.41 million shares as on 2025-03-31, resulting in a short ratio of 2.74. According to the data, the short interest in Lyra Therapeutics Inc (LYRA) stood at 459.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 1.88 million. The stock has fallen by -55.43% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LYRA stock heading into the next quarter.
